Ijsbrand T Klip1, Douwe Postmus2, Adriaan A Voors1, Frank P J Brouwers1, Ron T Gansevoort3, Stephan J L Bakker3, Hans L Hillege4, Rudolf A de Boer1, Pim van der Harst1, Wiek H van Gilst1, Dirk J van Veldhuisen1, Peter van der Meer5. 1. Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 2. Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3. Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 4. Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 5. Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: p.van.der.meer@umcg.nl.
Abstract
BACKGROUND: In established cardiovascular disease and heart failure (HF), low hemoglobin levels are associated with unfavorable outcome. Whether hemoglobin levels are associated with the development of new-onset HF in the population is unclear. This study sought to investigate the relationship between hemoglobin levels and development of new-onset HF in the community. METHODS: In 6,744 patients from PREVEND, a prospective, community-based, cohort study, we analyzed the relationship between hemoglobin levels and the risk of new-onset HF. RESULTS: Mean age (±SD) was 53 ± 12 years, 49.8% was male, and mean hemoglobin level was 13.7 ± 1.2 g/dL. During a median follow-up of 8.3 years (interquartile range 7.8-8.9), 217 subjects (3.2%) were newly diagnosed with HF. The association between hemoglobin levels and the risk for new-onset HF was U shaped (P< .001), remaining significant after full adjustment in a multivariable model with established cardiovascular risk factors (P= .015). Furthermore, a increased annual HF incidence was already observed in subjects with high-normal hemoglobin levels (men >16 g/dL or women >15 g/dL; P= .041), whereas on the other side of the distribution, only severe anemia (men <11 g/dL or women <10 g/dL; P= .018) was associated with a higher annual incidence. CONCLUSIONS: The impact of hemoglobin level on the risk of new-onset HF in the community is best described as U shaped. Interestingly, higher hemoglobin levels, already within the high-reference range, are associated with an increased incidence. This in contrast to anemia, where a higher annual HF incidence was only observed for severe anemia.
BACKGROUND: In established cardiovascular disease and heart failure (HF), low hemoglobin levels are associated with unfavorable outcome. Whether hemoglobin levels are associated with the development of new-onset HF in the population is unclear. This study sought to investigate the relationship between hemoglobin levels and development of new-onset HF in the community. METHODS: In 6,744 patients from PREVEND, a prospective, community-based, cohort study, we analyzed the relationship between hemoglobin levels and the risk of new-onset HF. RESULTS: Mean age (±SD) was 53 ± 12 years, 49.8% was male, and mean hemoglobin level was 13.7 ± 1.2 g/dL. During a median follow-up of 8.3 years (interquartile range 7.8-8.9), 217 subjects (3.2%) were newly diagnosed with HF. The association between hemoglobin levels and the risk for new-onset HF was U shaped (P< .001), remaining significant after full adjustment in a multivariable model with established cardiovascular risk factors (P= .015). Furthermore, a increased annual HF incidence was already observed in subjects with high-normal hemoglobin levels (men >16 g/dL or women >15 g/dL; P= .041), whereas on the other side of the distribution, only severe anemia (men <11 g/dL or women <10 g/dL; P= .018) was associated with a higher annual incidence. CONCLUSIONS: The impact of hemoglobin level on the risk of new-onset HF in the community is best described as U shaped. Interestingly, higher hemoglobin levels, already within the high-reference range, are associated with an increased incidence. This in contrast to anemia, where a higher annual HF incidence was only observed for severe anemia.
Authors: Odilson M Silvestre; Alexandra Gonçalves; Wilson Nadruz; Brian Claggett; David Couper; John H Eckfeldt; James S Pankow; Stefan D Anker; Scott D Solomon Journal: Eur J Heart Fail Date: 2016-12-14 Impact factor: 15.534
Authors: Joanna Sophia J Vinke; Marith I Francke; Michele F Eisenga; Dennis A Hesselink; Martin H de Borst Journal: Nephrol Dial Transplant Date: 2021-11-09 Impact factor: 5.992
Authors: S Heleen Binnenmars; Georgette E Hoogslag; Stanley M H Yeung; Frank P Brouwers; Stephan J L Bakker; Wiek H van Gilst; Ron T Gansevoort; Gerjan Navis; Adriaan A Voors; Martin H de Borst Journal: J Am Heart Assoc Date: 2022-07-25 Impact factor: 6.106
Authors: Noel Lorenzo Villalba; Belén Chiva Ballesteros; Laura De Pedro Álvarez; Pamen Delgado Mainar; Ángel Nieto Sánchez; Javier Marco Martínez; Elpidio Calvo Manuel; Manuel Méndez Bailon Journal: Pan Afr Med J Date: 2019-12-17